BR0111601A - Método para o tratamento de doença cardiovascular - Google Patents

Método para o tratamento de doença cardiovascular

Info

Publication number
BR0111601A
BR0111601A BR0111601-0A BR0111601A BR0111601A BR 0111601 A BR0111601 A BR 0111601A BR 0111601 A BR0111601 A BR 0111601A BR 0111601 A BR0111601 A BR 0111601A
Authority
BR
Brazil
Prior art keywords
treatment
cardiovascular disease
mammal
cardiovascular
disease
Prior art date
Application number
BR0111601-0A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0111601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0111601A publication Critical patent/BR0111601A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE DOENçA CARDIOVASCULAR". A invenção refere-se a um método para o tratamento ou a inibição de doença cardiovascular, vascular cerebral, ou vascular periférica em um mamífero que necessite do referido tratamento, que compreende proporcionar ao referido mamífero uma quantidade eficaz de uma rapamicina.
BR0111601-0A 2000-06-16 2001-06-14 Método para o tratamento de doença cardiovascular BR0111601A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16
PCT/US2001/019179 WO2001097809A2 (en) 2000-06-16 2001-06-14 Method of treating cardiovascular disease using rapamycin

Publications (1)

Publication Number Publication Date
BR0111601A true BR0111601A (pt) 2003-07-01

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111601-0A BR0111601A (pt) 2000-06-16 2001-06-14 Método para o tratamento de doença cardiovascular

Country Status (19)

Country Link
US (1) US20020013335A1 (pt)
EP (1) EP1292302A2 (pt)
JP (1) JP2003535899A (pt)
KR (1) KR20030010710A (pt)
CN (1) CN1436076A (pt)
AR (1) AR028959A1 (pt)
AU (2) AU6844601A (pt)
BR (1) BR0111601A (pt)
CA (1) CA2412636A1 (pt)
CZ (1) CZ20024115A3 (pt)
EA (1) EA200300027A1 (pt)
HU (1) HUP0301244A3 (pt)
IL (1) IL153405A0 (pt)
MX (1) MXPA02012410A (pt)
NO (1) NO20026008D0 (pt)
NZ (1) NZ523114A (pt)
PL (1) PL365455A1 (pt)
WO (1) WO2001097809A2 (pt)
ZA (1) ZA200300418B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
UA81265C2 (en) * 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (de) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
CN100435755C (zh) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN102803189B (zh) 2010-03-15 2016-01-20 埃克森美孚化学专利公司 用于生产醇的方法
US20150290176A1 (en) * 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN105997940A (zh) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 炎症微环境响应性纳米药物、其制备方法及应用
CN117224557A (zh) * 2023-11-02 2023-12-15 中国人民解放军空军军医大学 柚皮苷联合雷帕霉素在制备治疗高脂血症的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
TR199903065T2 (xx) * 1997-06-13 2000-09-21 American Home Products Corporation Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
HUP0301244A2 (hu) 2003-08-28
WO2001097809A3 (en) 2002-05-10
PL365455A1 (en) 2005-01-10
AR028959A1 (es) 2003-05-28
JP2003535899A (ja) 2003-12-02
EP1292302A2 (en) 2003-03-19
CZ20024115A3 (cs) 2003-06-18
ZA200300418B (en) 2004-04-15
HUP0301244A3 (en) 2005-01-28
IL153405A0 (en) 2003-07-06
US20020013335A1 (en) 2002-01-31
KR20030010710A (ko) 2003-02-05
AU2001268446B2 (en) 2005-08-11
NO20026008L (no) 2002-12-13
CN1436076A (zh) 2003-08-13
NO20026008D0 (no) 2002-12-13
AU6844601A (en) 2002-01-02
WO2001097809A2 (en) 2001-12-27
CA2412636A1 (en) 2001-12-27
EA200300027A1 (ru) 2003-06-26
MXPA02012410A (es) 2003-04-25
NZ523114A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
BR0016652A (pt) Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
BR0110084A (pt) Composições e métodos para melhorar saúde vascular
BR0206644A (pt) Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
CY1119109T1 (el) Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων
BR0215168A (pt) Métodos para retardar a senescência e tratamento e prevenção de doenças associadas com senescência
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS DIPEPTIDYLPEPTIDASEINHIBITORS FOR THE TREATMENT OF BZW. PREVENTION OF DIABETES
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
EP1635815A4 (en) METHOD AND COMPOUNDS FOR TREATING TISSUE TESTS
BRPI0408491A (pt) tratamento da doença de alzheimer
EP1335739A4 (en) VEGETABLE COMPOSITION FOR TREATING NERVE INJURY AND NEURONAL DEGENERATION, METHOD FOR PRODUCING SUCH COMPOSITION AND USES
EP1141251A4 (en) CONNECTIONS, SCREENING METHOD AND METHOD OF TREATING DISEASES OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
BR9808784A (pt) Método para o tratamento de doença mental em mamìferos e uma composição para o mesmo
BR0204620B1 (pt) processo para o tratamento de condensados que contÊm compostos.
MA27503A1 (fr) Composition et methode de traitement du diabete.
NO984160D0 (no) Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.